Study supported by Wellcome and Cancer Research UK is promising step toward new treatments for acute myeloid leukaemia. Research into the role of the protein, YTHDF2, in Acute Myeloid Leukaemia (AML) has identified YTHDF2 as a promising drug target for the treatment of AML. The role of YTHDF2 in AML was investigated by a team of researchers led by Dónal O’Carroll (WCB & CRM, University of Edinburgh) and Kamil Kranc (Queen Mary University of London). They have shown that YTHDF2 is needed to trigger and sustain the disease, but is not needed for healthy cells to function. This raises the possibility of developing new drugs with significantly fewer harmful side effects than existing chemotherapy. The study, carried out in collaboration with the University of Manchester, Harvard Medical School and the Université de Tours, was published in Cell Stem Cell. It was supported by Wellcome and Cancer Research UK. Paris, J., Morgan, M., Campos, J., Gregory, R.I., O’Carroll, D., Kranc, K.R. (2019) “Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia” Cell Stem Cell Published:April 25, 2019 DOI:https://doi.org/10.1016/j.stem.2019.03.021 This article was published on 2024-06-17
